Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company that focuses on developing innovative medicines for central nervous system disorders, including schizophrenia, depression, and addiction. The company operates in a competitive landscape with peers like Biogen and Amgen. Alkermes' recent activities have drawn attention, particularly with its stock performance and insider transactions.
On April 1, 2026, Craig C. Hopkinson, Alkermes' Executive Vice President of Research and Development and Chief Medical Officer, sold 9,000 Ordinary Shares at approximately $35.51 each. Despite this sale, Hopkinson still holds 85,389 shares. This transaction comes at a time when Alkermes' stock is experiencing significant momentum, as highlighted by Benzinga.
Alkermes' stock has recently shown strong performance, with a 23% increase over the past five days, reaching a 52-week high of $36.32. However, the stock's Relative Strength Index (RSI) is at 82.3, indicating it is overbought. Typically, an RSI above 70 suggests that a stock may be overvalued, which could be a concern for momentum-focused investors.
Despite the high RSI, Piper Sandler analyst David Amsellem maintains an Overweight rating on Alkermes, though he adjusted the price target from $45 to $43. The stock's Edge Stock Ratings momentum score is 78.64, and its value score is 63.98, reflecting its current market position. Alkermes' financial metrics, such as a P/E ratio of 23.89 and a price-to-sales ratio of 3.96, indicate the market's valuation of its earnings and revenue.
Alkermes also maintains a strong liquidity position with a current ratio of 3.55, suggesting it can cover short-term liabilities with its short-term assets. The company's debt-to-equity ratio is low at 0.038, indicating a conservative use of debt. These financial metrics provide insight into Alkermes' stability and potential for future growth.
